DebraLynnSimmonsMD
Endocrinology • Salt Lake City, UTDiabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology
Assistant Professor of Medicine, University Ark
Dr. Simmons is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
615 S Arapeen Dr
Ste 100
Salt Lake City, UT 84108Phone+1 801-587-3926Fax+1 801-587-3920
Education & Training
University of California (San Diego) Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1988
Indiana University School of MedicineResidency, Internal Medicine, 1982 - 1985
University of Texas Southwestern Medical SchoolClass of 1982
Certifications & Licensure
UT State Medical License 2012 - 2024
AR State Medical License 1997 - 2023
CA State Medical License 1985 - 2022
TX State Medical License 1983 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACE) American Association of Clinical Endocrinology
Publications & Presentations
PubMed
- 32 citationsEffect of Intensive Glycemic Lowering on Health-Related Quality of Life in Type 2 Diabetes: ACCORD trialRoger T. Anderson, K.M. Venkat Narayan, Patricia Feeney, David C. Goff, Mohammed K. Ali
Diabetes Care. 2011-04-01 - 30 citationsLong-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.Amy K. Mottl, John B. Buse, Faramarz Ismail-Beigi, Ronald J. Sigal, Carolyn F. Pedley
Clinical Journal of the American Society of Nephrology. 2018-11-07 - 701 citationsThe association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD studyDenise E. Bonds, Michael E. Miller, Richard M. Bergenstal, John B. Buse, Robert P. Byington
BMJ. 2010-01-08
Press Mentions
Experimental Drug Could Be New Option for Type 2 DiabetesJanuary 18th, 2019
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
